Vtv Theraptcs Cl A (VTVT) Stock Price, Quote & News

Company Profile

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 336 841 0300

Fax: 336 841 0310

Website: vtvtherapeutics.com

Address:

3980 Premier Drive, Suite 310, High Point, United States

km1663 Jun. 12 at 4:05 PM

$VTVT Can I get a push?

0 · Reply

VitoMcgehee690 Jun. 11 at 4:13 PM

$VTVT is struggling at support while AMBR is testing resistance with strength.

0 · Reply

GDS_investing Jun. 10 at 3:26 PM

$RFL great call here, glta my followers long and strong for p3 data NEWS still holding for long $AGEN $VTVT $SSKN

0 · Reply

GDS_investing Jun. 9 at 5:10 PM

$RFL great call here, glta my followers long and strong for p3 data NEWS still holding for long $AGEN $VTVT $SSKN

0 · Reply

GDS_investing Jun. 6 at 2:04 PM

$AGEN great call here glta my followers watch and add more $RFL and $VTVT for long run

1 · Reply

Jacks10 Jun. 4 at 10:39 PM

$VTVT time to break out of this $14-$22 range and shoot for the $30-40's.

0 · Reply

GDS_investing Jun. 2 at 5:37 PM

$VTVT

0 · Reply

dcajic2 May. 29 at 11:51 AM

$VTVT Just a no interest company. How long is it going to take for full enrolment? Can they really survive without a big injection of cash? What is happening with the study in Dubai? It’s a company that pays their executives millions a year and yet really doesn’t keep investors informed of what is really going on. They had a clinical hold for almost 8 months and didn’t say a word

0 · Reply

dcajic2 May. 27 at 8:47 PM

$VTVT Who are the actual sellers or the buyers for that matter

1 · Reply

Jacks10 May. 27 at 6:52 PM

$VTVT who's dropping the share price ever so slowly?

2 · Reply

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

May 19, 2025, 9:00 AM EDT - 4 weeks ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 15, 2025, 4:01 PM EDT - 4 weeks ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 12:00 PM EDT - 4 weeks ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Mar 20, 2025, 5:35 PM EDT - 3 months ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 17, 2025, 1:59 PM EDT - 3 months ago

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

Mar 17, 2025, 8:30 AM EDT - 3 months ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Dec 9, 2024, 7:33 AM EST - 6 months ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 2, 2024, 4:05 PM EST - 7 months ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Aug 8, 2024, 4:15 PM EDT - 11 months ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Jul 26, 2024, 4:05 PM EDT - 11 months ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jun 24, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

May 28, 2024, 8:00 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 9, 2024, 4:51 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

Mar 19, 2024, 8:30 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 13, 2024, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 4, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 1, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Feb 28, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 22, 2024, 4:00 PM EST - 1 year ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Nov 9, 2023, 4:30 PM EST - 1 year ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2023, 8:00 AM EST - 1 year ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 2, 2023, 8:00 AM EDT - 1 year ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 1, 2023, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Sep 27, 2023, 8:30 AM EDT - 1 year ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

$Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer$

Sep 26, 2023, 8:30 AM EDT - 1 year ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 18, 2023, 8:30 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Aug 11, 2023, 4:30 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 10, 2023, 8:33 AM EDT - 2 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Jun 16, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 15, 2023, 7:33 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

May 24, 2023, 9:00 AM EDT - 2 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 11, 2023, 4:15 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Apr 20, 2023, 8:00 AM EDT - 2 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Mar 6, 2023, 5:56 PM EST - 2 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 6, 2023, 8:02 AM EST - 2 years ago

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Feb 27, 2023, 8:02 AM EST - 2 years ago

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Feb 1, 2023, 5:00 PM EST - 2 years ago

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

Jan 9, 2023, 8:00 AM EST - 2 years ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Dec 13, 2022, 8:15 AM EST - 2 years ago

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

Nov 10, 2022, 5:25 PM EST - 2 years ago

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

Aug 15, 2022, 6:43 PM EDT - 3 years ago

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

Jul 27, 2022, 7:00 AM EDT - 3 years ago

vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer

Jul 25, 2022, 7:00 AM EDT - 3 years ago

vTv Therapeutics Announces Investment by CinRx Pharma

Jun 4, 2022, 11:00 AM EDT - 3 years ago

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Jun 1, 2022, 6:54 AM EDT - 3 years ago

vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare

May 12, 2022, 7:45 AM EDT - 3 years ago

vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update

Mar 29, 2022, 9:47 PM EDT - 3 years ago

vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 3, 2022, 8:48 PM EST - 3 years ago

vTv Therapeutics Announces CEO Transition

Jan 13, 2022, 8:30 AM EST - 3 years ago

vTv Therapeutics Shares Updated Corporate Presentation

km1663 Jun. 12 at 4:05 PM

$VTVT Can I get a push?

0 · Reply

VitoMcgehee690 Jun. 11 at 4:13 PM

$VTVT is struggling at support while AMBR is testing resistance with strength.

0 · Reply

GDS_investing Jun. 10 at 3:26 PM

$RFL great call here, glta my followers long and strong for p3 data NEWS still holding for long $AGEN $VTVT $SSKN

0 · Reply

GDS_investing Jun. 9 at 5:10 PM

$RFL great call here, glta my followers long and strong for p3 data NEWS still holding for long $AGEN $VTVT $SSKN

0 · Reply

GDS_investing Jun. 6 at 2:04 PM

$AGEN great call here glta my followers watch and add more $RFL and $VTVT for long run

1 · Reply

Jacks10 Jun. 4 at 10:39 PM

$VTVT time to break out of this $14-$22 range and shoot for the $30-40's.

0 · Reply

GDS_investing Jun. 2 at 5:37 PM

$VTVT

0 · Reply

dcajic2 May. 29 at 11:51 AM

0 · Reply

dcajic2 May. 27 at 8:47 PM

$VTVT Who are the actual sellers or the buyers for that matter

1 · Reply

Jacks10 May. 27 at 6:52 PM

$VTVT who's dropping the share price ever so slowly?

2 · Reply

jarich7 May. 23 at 5:49 PM

$VTVT

0 · Reply

dcajic2 May. 19 at 7:01 PM

$VTVT still no interest. Most people don’t even know it exists

0 · Reply

km1663 May. 19 at 6:09 PM

$VTVT If we can get some volume with these releases. https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-appoints-michael-tung-md-mba-chief-financial

0 · Reply

Bullfinch2 May. 15 at 8:03 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-2025-first-quarter-financial-results

0 · Reply

dcajic2 May. 15 at 6:24 PM

$VTVT Finally a little good news with this company and there still is pretty much no interest

0 · Reply

Bullfinch2 May. 15 at 4:26 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-reinitiation-screening-catt1-phase-3

0 · Reply

GDS_investing May. 15 at 4:25 PM

$VTVT looking great and strong a lot of room to run here 56$ and 150$ area Huge potential for success for this company do yours dd LONG and STRONG $VTVT

0 · Reply

GDS_investing May. 15 at 4:20 PM

$VTVT great NEWS just out: "vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes" https://finance.yahoo.com/news/vtv-therapeutics-announces-reinitiation-screening-160000588.html very low float only 640k volume is the key watch $CLIK $NAKA

1 · Reply

AZOZ May. 14 at 6:45 PM

$VTVT micro floater could skyrocketing if strong PR hit the wire Stay tuned!

0 · Reply

dcajic2 May. 12 at 7:14 PM

$VTVT Do the math yourself . Try float is much more than 640k

0 · Reply

GDS_investing May. 12 at 6:59 PM

$VTVT Haven't joined the party yet very low float only 640k volume is the key watch $AGEN $INVZ $TNA

0 · Reply

Doozio May. 12 at 6:00 PM

$VTVT chop chop huckleberries INTA 🐒🍌🧠⏰♾️. Barring a faaatch 💣. Obviously

0 · Reply

Market Cap	49.04M
Revenue (ttm)	1.02M
Net Income (ttm)	-18.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,809.80%
Debt to Equity Ratio	0.00

Volume	800
Avg Vol	8,008
Day's Range	N/A - N/A
Shares Out	3.20M
Stochastic %K	40%
Beta	0.59
Analysts	Strong Sell
Price Target	$35.50